Brazil's Anvisa Halts Imports of French Eye Drops and Gels Due to Manufacturing Violations
Brazil's National Health Surveillance Agency (Anvisa) has ordered a halt to the importation of all medications produced by the French company Excelvision. This preventive measure, published on Friday, May 17th, in the Official Gazette, aims to prevent these products from entering the Brazilian market. The decision follows an inspection by France's National Agency for the Safety of Medicines and Health Products (ANSM) in June, which revealed that Excelvision failed to comply with good manufacturing practices for medicines. Consequently, the French agency issued an international health alert, which Anvisa has now adopted. In addition to the general import suspension for Excelvision products, Anvisa has specifically prohibited the import of Zonidra - 20 MG/ML X 5 ML. Although this medication is manufactured by Excelvision and has prior registration in Brazil, it has never been sold domestically. Furthermore, all batches of Hyabak and Thealiz Duo manufactured at Excelvision's factory from June 5th, 2026, onwards are also suspended. Consumers are advised against using these products, to check product labeling for the manufacturing location, and to contact the company directly.
Anvisa's swift action to suspend imports from Excelvision, prompted by French regulatory findings, highlights the critical role of international regulatory cooperation in ensuring pharmaceutical safety. The agency's proactive stance, extending beyond specific products to all items from the implicated manufacturer, underscores a commitment to public health by mitigating potential risks associated with non-compliance with good manufacturing practices. This event serves as a reminder of the complex global supply chains in the pharmaceutical industry and the inherent vulnerabilities that arise when manufacturing standards are compromised. Future considerations may involve enhanced oversight mechanisms for imported pharmaceuticals, particularly those originating from regions with identified compliance issues, to safeguard consumer health and maintain market integrity.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.